Entity Detail — Knowledge Graph Node
This page aggregates everything SciDEX knows about AR: its mechanistic relationships (Knowledge Graph edges), hypotheses targeting it, analyses mentioning it, and supporting scientific papers. The interactive graph below shows its immediate neighbors. All content is AI-synthesized from peer-reviewed literature.
A gene referenced in 165 knowledge graph relationships. Key connections: interacts_with SLIRP (protein); interacts_with IGFBP5 (protein); contributes_to Androgen Deprivation Therapy Resistance (phenotype).
No AI portrait yet
| Gene Symbol | AR |
| Chromosome | Xq12 |
| Protein Type | Gene |
| Function | encodes a nuclear receptor protein that binds testosterone and dihydrotestosterone, mediating the effects of androgen hormones in target tissues. |
| Primary Expression | brain regions including: - Spinal cord: Motor neurons, including those innervating skeletal muscle - Hypothalamus: Regulatory centers for hor |
| Molecular Weight | 110 kDa |
| Amino Acids | 919 aa |
| GeneCards | AR |
| Human Protein Atlas | AR |
| N-terminal domain (NTD) | Contains the AF-1 activation function and polyQ tract |
| DNA-binding domain (DBD) | Two zinc finger motifs for GRE binding |
| Hinge region | Contains the nuclear localization signal |
| Ligand-binding domain (LBD) | Binds testosterone/DHT; contains AF-2 |
| Spinal cord | Motor neurons, including those innervating skeletal muscle |
| Hypothalamus | Regulatory centers for hormone release |
| Associated Diseases | Aromatase Inhibitor Resistance, cancer |
| Known Drugs/Compounds | rapamycin |
| Interactions | ACTB, AKT, ALS, AMBRA1, AMPK, APP |
| SciDEX Hypotheses | Testosterone-Derived DHT Amplifies Microglial Andr |
| KG Connections | 178 knowledge graph edges |
| Databases | GeneCardsUniProtNCBI GeneHPASTRING |
Knowledge base pages for this entity
flowchart TD
A["AR"] --> B["Androgen Binding"]
A --> C["Nuclear Translocation"]
B --> C
C --> D["Gene Transcription"]
D --> E["Mitochondrial Biogenesis"]
D --> F["Neuronal Survival Genes"]
E --> G["ATP Production"]
G --> H["Neuronal Bioenergetics"]
F --> I["Anti-apoptotic Effect"]
H --> J["Neuroprotection"]
I --> J
A --> K["SLIRP Interaction"]| Target | Relation | Type | Str |
|---|---|---|---|
| benchmark_ot_ad_answer_key:AR | data_in | dataset_row | 0.00 |
| SLIRP | interacts_with | protein | 0.95 |
| IGFBP5 | interacts_with | protein | 0.95 |
| oxidative stress response | participates_in | pathway | 0.90 |
| Androgen Deprivation Therapy Resistance | contributes_to | phenotype | 0.90 |
| Metabolic Adaptation | modulates | process | 0.90 |
| autophagy pathway | participates_in | pathway | 0.90 |
| Aromatase Inhibitor Resistance | associated_with | phenotype | 0.85 |
| Prostate Cancer Cell Survival | regulates | phenotype | 0.80 |
| androgen deprivation therapy resistance | mediates | phenotype | 0.80 |
| epigenetic regulation | participates_in | pathway | 0.80 |
| BECN1 | activates | gene | 0.80 |
| MAP1LC3B | activates | gene | 0.80 |
| IL12A | inhibits | gene | 0.80 |
| Sex Differences In Autophagy | modulates | mechanism | 0.75 |
| Autophagy | regulates | process | 0.75 |
| MAPK signaling | participates_in | pathway | 0.70 |
| CHMP4B | activates | gene | 0.70 |
| ATG | activates | gene | 0.70 |
| Parkinson's disease | activates | disease | 0.70 |
| RNA | activates | gene | 0.70 |
| stem cells | expressed_in | cell_type | 0.70 |
| SQSTM1 | activates | gene | 0.70 |
| LAMP1 | activates | gene | 0.70 |
| HDAC6 | activates | gene | 0.70 |
| Parkinson's disease | interacts_with | disease | 0.70 |
| PIK3C3 | activates | gene | 0.70 |
| TFEB | activates | gene | 0.70 |
| GAPDH | activates | gene | 0.70 |
| UVRAG | activates | gene | 0.70 |
| MTOR | activates | gene | 0.70 |
| GABA | activates | gene | 0.70 |
| GLA | activates | gene | 0.70 |
| BCL2 | activates | gene | 0.70 |
| PPP3CB | activates | gene | 0.60 |
| SOD1 | activates | gene | 0.60 |
| STIP1 | activates | gene | 0.60 |
| STUB1 | activates | gene | 0.60 |
| TARDBP | activates | gene | 0.60 |
| TPP1 | activates | gene | 0.60 |
| TREH | activates | gene | 0.60 |
| neurodegeneration | activates | disease | 0.60 |
| ATG14 | activates | gene | 0.60 |
| CASP3 | activates | gene | 0.60 |
| CDC42 | activates | gene | 0.60 |
| GJA1 | activates | gene | 0.60 |
| H2AX | activates | gene | 0.60 |
| MAP3K5 | activates | gene | 0.60 |
| OCLN | activates | gene | 0.60 |
| RAC1 | activates | gene | 0.60 |
| Source | Relation | Type | Str |
|---|---|---|---|
| benchmark_ot_ad_answer_key:AR | data_in | dataset_row | 0.00 |
| SPOP | degrades | protein | 0.90 |
| PI3K-AKT-mTOR | interacts_with | pathway | 0.85 |
| Stress Granules | modulates | process | 0.85 |
| SPOP mutations | promotes | phenotype | 0.85 |
| rapamycin | targets | drug | 0.70 |
| ALS | activates | gene | 0.60 |
| ALOX12 | associated_with | gene | 0.60 |
| AMPK | activates | gene | 0.60 |
| ACTB | activates | gene | 0.60 |
| AMBRA1 | activates | gene | 0.60 |
| APP | activates | gene | 0.60 |
| AKT | associated_with | gene | 0.60 |
| AKT | inhibits | gene | 0.60 |
Hypotheses where this entity is a therapeutic target
Scientific analyses that reference this entity
neurodegeneration | 2026-04-28 | 7 hypotheses Top: 0.662
neurodegeneration | 2026-04-28 | 3 hypotheses Top: 0.604
neurodegeneration | 2026-04-27 | 3 hypotheses Top: 0.604
neurodegeneration | 2026-04-27 | 3 hypotheses Top: 0.604
neurodegeneration | 2026-04-16 | 0 hypotheses
Experimental studies targeting or related to this entity
| Experiment | Type | Disease | Score | Feasibility | Model | Status | Est. Cost |
|---|---|---|---|---|---|---|---|
| Plant-based dietary patterns and Alzheimer's disease risk in multiethn | clinical | Alzheimer's disease and relate | 0.950 | 0.00 | human patients | proposed | N/A |
| CSF Dynamic Biomarkers for Differential Diagnosis of NPH vs AD with Co | clinical | Alzheimer's Disease | 0.900 | 0.50 | aortic endothelial cells | proposed | $6,550,000 |
| SIRPα modulation in mouse models of Alzheimer's disease | validation | Alzheimer's disease | 0.900 | 0.00 | mouse models of Alzheimer's di | proposed | N/A |
| s:** - Test tau spreading in AQP4 knockout vs wild-type mice with PSP/ | falsification | Neurodegeneration | 0.400 | 0.50 | mouse | proposed | $260,000 |
| Circadian-Vascular-Metabolic Syndrome (CVMS) Intervention Trial | clinical | Neurodegeneration | 0.400 | 0.50 | human | proposed | $3,900,000 |
| DLB Cognitive Fluctuation Mechanism Experiment | clinical | Neurodegeneration | 0.400 | 0.50 | human | proposed | $6,550,000 |
| Glymphatic-Circadian Axis Enhancement Therapy for Parkinson's Disease | clinical | Parkinson's Disease | 0.400 | 0.50 | human | proposed | $5,460,000 |
| Non-Motor Symptom Progression in Parkinson's Disease — Mechanisms and | clinical | Parkinson's Disease | 0.400 | 0.50 | human | proposed | $5,460,000 |
| NPH Glymphatic System Interaction Experiment | clinical | Neurodegeneration | 0.400 | 0.50 | human | proposed | $5,460,000 |
| Sleep and Circadian Dysfunction as Driver of Neurodegeneration | clinical | Neurodegeneration | 0.400 | 0.50 | human | proposed | $5,460,000 |
| Sleep Disruption and Alzheimer's Disease — mechanism and intervention | clinical | Alzheimer's Disease | 0.400 | 0.50 | human | proposed | $5,460,000 |
| Sleep and Respiratory Network Interaction in ALS — Experiment Design | clinical | ALS | 0.400 | 0.50 | human | proposed | $5,460,000 |
Scientific publications cited in analyses involving this entity
| Title & PMID | Authors | Journal | Year | Citations |
|---|---|---|---|---|
| Combined effects of HCRTR1/2 gene variants and non-genetic factors on sleep-wake [PMID:40439868] | Zheng Z, Xue F, Wang H, Gu Q, Hu R, Li X | Pharmacol Rep | 2025 | 1 |
| Genetic determinants of daytime napping and effects on cardiometabolic health. [PMID:33568662] | Dashti HS, Daghlas I, Lane JM, Huang Y, | Nat Commun | 2021 | 1 |
| Hypocretin/Orexin Receptor Pharmacology and Sleep Phases. [PMID:34052813] | Sun Y, Tisdale RK, Kilduff TS | Front Neurol Neurosci | 2021 | 1 |
| Sleep drives metabolite clearance from the adult brain. [PMID:24136970] | Xie L, Kang H, Xu Q, Chen MJ, Liao Y, Th | Science | 2013 | 1 |
| Enhancing TREM2 expression activates microglia and modestly mitigates tau pathol [PMID:40122810] | ["Chen Kai", "Li Fuyao", "Zhang Shuwen", | Journal of neuroinflammation | 2025 | 0 |
| Signal transduction, dimerization, and therapeutic targeting of Orexin and recep [PMID:41383480] | Zhang S, Wang P, Ji B, Shao Y, Hou S et | Front Pharmacol | 2025 | 0 |
| Enhancing TREM2 expression activates microglia and modestly mitigates tau pathol [PMID:40122810] | ["Chen Kai", "Li Fuyao", "Zhang Shuwen", | Journal of neuroinflammation | 2025 | 0 |
| Increased Neuronal Expression of the Early Endosomal Adaptor APPL1 Replicates Al [PMID:40514243] | Jiang Y, Sachdeva K, Goulbourne CN, Berg | The Journal of neuroscience : | 2025 | 0 |
| Targeting Neural Oscillations for Cognitive Enhancement in Alzheimer’s Disease [PMID:40142358] | Federica Palacino, P. Manganotti, A. Ben | {'name': 'Medicina', 'volume': | 2025 | 0 |
| Bioinformatic analysis of neuropeptide related genes in patients diagnosed with [PMID:39437604] | Yay F, Ayan D | Comput Biol Med | 2024 | 0 |
| Effects of Paradoxical Sleep Deprivation on MCH and Hypocretin Systems. [PMID:39698172] | Agamme ALDA, Tufik S, Torterolo P, D'Alm | Sleep science (Sao Paulo, Braz | 2024 | 0 |
| P-tau217 correlates with neurodegeneration in Alzheimer's disease, and targeting [PMID:38513667] | Zhang D, Zhang W, Ming C, Gao X, Yuan H, | Neuron | 2024 | 0 |
| The necroptosis cell death pathway drives neurodegeneration in Alzheimer's disea [PMID:38852117] | Balusu S, De Strooper B | Acta neuropathologica | 2024 | 0 |
| Neuropathology of incidental Lewy body & prodromal Parkinson's disease. [PMID:37173733] | Koeglsperger T, Rumpf SL, Schließer P, S | Molecular neurodegeneration | 2023 | 0 |
| Blast Exposure Induces Acute Alterations in Circadian Clock Genes in the Hypotha [PMID:41127649] | Govindarajulu M, Patel MY, Krishnan J, L | Neurotrauma reports | 2023 | 0 |
| Contextual generalization of social stress learning is modulated by orexin recep [PMID:35724928] | Yaeger JDW, Krupp KT, Summers TR, Summer | Neuropharmacology | 2022 | 0 |
| Evaluation of the α-casein (CSN1S1) locus as a potential target for a site-speci [PMID:35568783] | ["Smirnov A", "Kontsevaya G", "Shnaider | Scientific reports | 2022 | 0 |
| Outcomes of a telemedicine bowel management program during COVID-19. [PMID:34686377] | ["Knaus M", "Ahmad H", "Metzger G", "Bey | Journal of pediatric surgery | 2022 | 0 |
| Chemical genetic activation of the cholinergic basal forebrain hippocampal circu [PMID:35418161] | Weilin Liu, Jianhong Li, Minguang Yang | {'name': "Alzheimer's Research | 2022 | 0 |
| Sleep interventions in AD trials show inconsistent cognitive benefits, possibly [PMID:33661831] | Unknown | Sleep Medicine Reviews | 2021 | 0 |
Multi-agent debates referencing this entity
closed · Rounds: 4 · Score: 0.76 · 2026-04-28
closed · Rounds: 4 · Score: 0.64 · 2026-04-28
closed · Rounds: 4 · Score: 0.64 · 2026-04-28
closed · Rounds: 4 · Score: 0.64 · 2026-04-28
closed · Rounds: 4 · Score: 0.50 · 2026-04-21
closed · Rounds: 0 · Score: 0.50 · 2026-04-21
closed · Rounds: 0 · Score: 0.56 · 2026-04-21
closed · Rounds: 0 · Score: 0.48 · 2026-04-21
closed · Rounds: 0 · Score: 0.51 · 2026-04-21
closed · Rounds: 4 · Score: 0.73 · 2026-04-21
Hypotheses and analyses mentioning AR in their description or question text
Score: 0.884 · Alzheimer's disease · 2026-04-05
## Mechanistic Overview Beta-frequency entrainment therapy targeting PV interneuron-astrocyte coupling for tau clearance
Score: 0.882 · neurodegeneration · 2026-04-02
## Mechanistic Overview Circadian Glymphatic Entrainment via Targeted Orexin Receptor Modulation starts from the claim t
Score: 0.869 · Alzheimer's disease · 2026-04-05
## Mechanistic Overview Closed-loop tACS targeting EC-II parvalbumin interneurons to restore gamma rhythmogenesis and bl
Score: 0.868 · ALS · 2026-04-27
RBM45 (RNA Binding Motif Protein 45) is a predominantly neuronal RNA-binding protein that undergoes ALS-associated disea
Score: 0.865 · Alzheimer's disease · 2026-04-07
## Mechanistic Overview Optogenetic restoration of hippocampal gamma oscillations via selective PV interneuron activatio
Score: 0.865 · neuroscience · 2026-04-07
## Mechanistic Overview Glymphatic-Mediated Tau Clearance Dysfunction starts from the claim that modulating MAPT within
Score: 0.864 · ALS · 2026-04-27
SFPQ (Splicing Factor Proline-Glutamine Rich) is a non-POU domain octamer binding protein (NONO) family member that func
Score: 0.863 · Alzheimer's disease · 2026-04-07
## Mechanistic Overview Closed-loop focused ultrasound targeting EC-II PV interneurons to restore theta-gamma coupling a
Score: 0.862 · neurodegeneration · 2026-04-16
## Mechanistic Overview TREM2 R47H Variant-Driven Metabolic Dysfunction as the Primary Trigger for Failed DAM Transition
Score: 0.861 · neuroscience · 2026-04-12
## Mechanistic Overview TREM2-Mediated Microglial Dysfunction Disrupts Perivascular Tau Clearance starts from the claim
Score: 0.844 · neurodegeneration · 2026-04-16
## Mechanistic Overview TYROBP (DAP12) Conditional Antagonism for Early-Stage Neuroprotection starts from the claim that
Score: 0.843 · neurodegeneration · 2026-04-16
## Mechanistic Overview miR-155/Interferon-gamma Feedback Loop as a Reversible Molecular Switch for Protective Microglia
Score: 0.838 · neurodegeneration · 2026-04-17
## Mechanistic Overview Sequential Iron Chelation (Deferoxamine) and GPX4 Restoration (Sulforaphane) Prevents the Self-A
Score: 0.829 · translational neuroscience · 2026-04-16
## Mechanistic Overview Ketone Utilization Index as Metabolic Flexibility Biomarker starts from the claim that modulatin
Score: 0.827 · neuroscience · 2026-04-07
## Mechanistic Overview Microglial-Mediated Tau Clearance Dysfunction via TREM2 Signaling starts from the claim that mod